CBIO

Crescent Biopharma, Inc.

CBIO.US crescentbiopharma.com + Research + Basket
ISIN KYG2545C1042
Employees 69
Phone 617 460 5595
Fiscal year end December
IPO Jan 10, 2014
Address 300 Fifth Avenue, Waltham, MA, United States, 02451
13.22
-0.05 (-0.38%)
USD · NASDAQ
52-week range
8.72
27.41
Trading at 24% of the 52-week range
Market Cap
492.94M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
4.77
Div. Yield
N/A
% Institutions
82.83%
% Insiders
0.268%

1 Year

+2.1%

3 Year

-89.8%

10 Year

-97.8%
Description

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.

Actions

Add an action for CBIO.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Mr. Joshua T. Brumm CEO & Director 1978
Dr. Jonathan McNeill M.D. President & COO 1985
Dr. Ellie Im M.D. Chief Medical Officer 1978
Mr. Richard William Scalzo M.B.A. Chief Financial Officer 1986
Mr. Ryan Lynch Senior VP of Finance, Treasurer & Chief Accounting Officer 1984
Dr. Wenjie Cheng Ph.D. Senior Vice President of Technical Operations NA
Dr. Jan Pinkas Ph.D. Chief Scientific Officer 1969
Ms. Barbara Bispham Hale J.D. General Counsel & Corporate Secretary 1987
Ms. Amy Reilly Chief Communications Officer 1974
Mr. Christopher Doughty Chief Business Officer 1988

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Dec 04, 2025 Fairmount Funds Management Llc N/A Purchase 1.36M $13.41 $18.24M SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
FMR Inc 4.13M Jun 30, 2026 11.13% $0.00 0.00%
Bvf Inc 2.75M Jun 30, 2026 7.40% $1.27 0.00%
Fairmount Funds Management LLC 2.75M Jun 30, 2026 7.40% $3.27 0.00%
VR Adviser, LLC 2.13M Jun 30, 2026 5.74% $1.16 0.00%
Logos Global Management LP 1.90M Jun 30, 2026 5.11% $1.47 293.78%
FCPM III SERVICES BV 1.68M Jun 30, 2026 4.52% $4.02 0.00%
Balyasny Asset Management LLC 1.66M Jun 30, 2026 4.48% $0.04 10.12%
Vestal Point Capital LP 1.63M Jun 30, 2026 4.39% $0.69 8.67%
Opaleye Management Inc 1.32M Jun 30, 2026 3.55% $2.15 0.51%
BlackRock Inc 1.27M Jun 30, 2026 3.42% $0.00 998.95%
TANG CAPITAL MANAGEMENT LLC 1.16M Jun 30, 2026 3.12% $0.95 0.00%
Vanguard Capital Management, LLC 767.76K Jun 30, 2026 2.07% $0.00 -4.20%
Boxer Capital Management, LLC 453.69K Jun 30, 2026 1.22% $0.62 0.00%
Millennium Management LLC 403.86K Jun 30, 2026 1.09% $0.00 24.82%
Geode Capital Management, LLC 384.58K Jun 30, 2026 1.04% $0.00 269.00%
Jennison Associates LLC 378.51K Jun 30, 2026 1.02% $0.00 147.43%
NEXTBio Capital Management LP 372.86K Jun 30, 2026 1.00% $3.09 0.00%
RTW INVESTMENTS, LLC 372.86K Jun 30, 2026 1.00% $0.06 0.00%
Remedium Capital Partners, LLC 361.25K Jun 30, 2026 0.97% $1.44 0.00%
State Street Corp 315.59K Jun 30, 2026 0.85% $0.00 707.81%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Fidelity Small Cap Growth 950.82K 2.56% ▲ 83.37% Jul 31, 2026
2 Fidelity Growth Company Fund 939.16K 2.53% ▲ 221.28% Aug 31, 2026
3 Vanguard MStar Total Stk Mkt Idx Invest 906.65K 2.44% ▲ 0.00% Sep 30, 2026
4 iShares Russell 2000 ETF 738.08K 1.99% ▼ 1.14% Sep 30, 2026
5 Fidelity Small Cap Growth K6 461.30K 1.24% ▲ 92.36% Jul 31, 2026
6 Fidelity Advisor Biotechnology I 456.59K 1.23% ▲ 28.22% Aug 31, 2026
7 Fidelity Select Biotechnology 339.56K 0.91% ▲ 78.32% Aug 31, 2026
8 State Street® SPDR® S&P® Biotech ETF 334.66K 0.90% ▼ 1.88% Sep 30, 2026
9 PGIM Jennison Health Sciences Z 311.39K 0.84% ▲ 0.00% Sep 30, 2026
10 Fidelity Select Health Care 308.25K 0.83% ▲ 2.12% Aug 31, 2026

Financial Highlights

▼
Market Cap: $492.94M
EBITDA: $-170.03M
Book Value: $4.77
Earnings/Share: $-7.63
Profit Margin: 0.00%
Operating Margin: -1,432.64%
ROA (TTM): -69.15%
ROE (TTM): -160.75%
Revenue (TTM): $11.88M
Revenue/Share (TTM): $0.43
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $307.84M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 37.14M
Shares Float: 27.03M
% Insiders: 0.268%
% Institutions: 82.83%
Short % Float: 22.07%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$10.84M
Cost of Goods Sold
adjust
$-84.00K
Gross Profit
subtotal
$10.84M
SG&A
adjust
$-25.39M
R&D
adjust
$-138.09M
Operating Income
subtotal
$-152.63M
Other / Non-Operating Items
adjust
$-1.31M
Net Income
subtotal
$-153.94M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about CBIO.US!